Stock Comparison

JNJ vs REPL

Johnson & Johnson vs Replimune Group Inc

The Verdict

REPL takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

REPL

Replimune Group Inc

4.5

out of 10

Proceed with Caution

Head-to-Head

$557.1B

Market Cap

$405M

26.5

P/E Ratio

-1.4

21.8%

Profit Margin

N/A

26.3%

Return on Equity

-102.7%

0.6

Debt-to-Equity

0.2

Conservative

Overall Risk

Aggressive

1.0

DVR Score

4.5

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

REPL4.5/10

Replimune (REPL) now faces a significantly heightened risk profile following the FDA's second Complete Response Letter (CRL) for RP1 in anti-PD-1-failed melanoma. This crucial setback invalidates the primary near-term catalyst and severely delays commercialization, pushing out any potential 10x growth within the 3-5 year timeframe. The market has reacted with a ~60% stock decline, widespread analy...

Full REPL Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.